Anzeige
Mehr »
Montag, 09.02.2026 - Börsentäglich über 12.000 News
Goldman sieht 15.000 USD bei Kupfer - dieser Explorer ist noch völlig unbekannt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
383 Leser
Artikel bewerten:
(2)

Sunzen Group Berhad Sees Shareholders Support in AGM with Approval in All 9 Resolutions

Shareholders Unanimously Endorse Strategic Initiatives, Rebranding, and Governance Enhancements

PETALING JAYA, MALAYSIA / ACCESSWIRE / December 19, 2024 / Sunzen Group Berhad ("Sunzen" or "the Group"), formally known as Sunzen Biotech Berhad and an established player in Malaysia's health, medical devices and services, and finance sector with a diversified portfolio, successfully concluded its Nineteenth Annual General Meeting ("19th AGM") held at Kota Permai Golf & Country Club, Shah Alam. The AGM saw strong shareholder participation and approval of all resolutions tabled, marking a pivotal milestone for the Group as it continues to deliver value to its stakeholders.

Sunzen Group Berhad

Among the key resolutions approved was the Directors' fees and benefits for the extended financial period of 1 January 2024 to 30 June 2025, reflecting the Board's commitment to fostering a high level of governance and oversight. Shareholders also approved the re-election of three directors, namely Mr. Ching Chee Pun, Mr. Lee Yew Weng, and Puan Aida Lim Binti Abdullah, ensuring continuity in leadership and strategic direction for Sunzen.

In a landmark decision, shareholders approved a special resolution to rename the company from "Sunzen Biotech Berhad" to "Sunzen Group Berhad." This rebranding signals the Group's evolution into a diversified entity encompassing health, medical devices and services, and loan financing, while maintaining its commitment to meeting customer needs and demands over the long term.

The AGM further underscored the Group's commitment to sustainable growth with the renewal of the general mandate for share issuance under Section 75 of the Companies Act 2016. This mandate empowers the Board to issue shares of up to 10% of the Group's issued capital to support future strategic initiatives, including working capital, investments, and acquisitions, without the need for a separate general meeting.

Another resolution passed was the renewal of the Group's authority to purchase up to 10% of its issued shares. This move reflects Sunzen's proactive capital management strategy to enhance shareholder value. The Group also obtained shareholder approval for the continuation of Mr. Khoo Kien Hoe as an Independent Non-Executive Director, recognising his invaluable contributions and extensive experience.

Speaking at the AGM, Group Managing Director of Sunzen Group Berhad, Mr. Teo Yek Ming expressed his gratitude to the shareholders for their unwavering support. He commented, "The approval of these resolutions marks a new milestone for Sunzen as we align our strategies to capitalise on emerging opportunities. The adoption of the new name, Sunzen Group Berhad, symbolises our growth beyond the biotechnology sector, positioning us as a multifaceted organisation ready to deliver greater value to our shareholders."

"The Group will continually explore new opportunities across various industries, aiming to establish individual ecosystems within the fields of health and wellness products, medical devices and services, as well as loan financing, striving to become a sustainable and long-term enterprise." Mr. Teo added.

As Sunzen embarks on its next phase of growth, the Group remains committed to operational excellence and sustainable business practices, ensuring long-term profitability while navigating a dynamic business environment.

ABOUT SUNZEN GROUP BERHAD

Sunzen Group Berhad ("Sunzen"), incorporated in 2005, is a diversified company with core businesses spanning health and wellness products,medical devices and services, and loan financing. The Group is principally involved in the manufacturing and trading of health foods and beverages, offering a wide range of products including bird's nest, collagen drinks, herbal supplements, and traditional remedies. Sunzen also operates in loan financing and continues to expand its portfolio through strategic acquisitions and partnerships.

For more information, visit www.sunzen.com.my.

Issued By: Swan Consultancy Sdn. Bhd. on behalf of Sunzen Group Berhad

For more information, please contact:

Jazzmin Wan
Email: j.wan@swanconsultancy.biz
William Yeo
Email: w.yeo@swanconsultancy.biz

SOURCE: Sunzen Group Berhad


View the original press release on accesswire.com

© 2024 ACCESS Newswire
Vorsicht, geheim!
2026 startet mit einem Paukenschlag: Der DAX outperformt den US-Markt, Nachzügler holen auf. Ein erstes Signal, dass der Bullenmarkt an Breite gewinnt. Während viele Anleger weiter auf die großen Tech-Namen setzen, hat sich im Hintergrund längst ein Umschwung vollzogen. Der Fokus verschiebt sich weg von überteuerten KI-Highflyern hin zu soliden Qualitätswerten aus der zweiten Reihe.

Anleger, die jetzt clever agieren, setzen nicht auf das, was war, sondern auf das, was kommt. Unternehmen mit gesunder Bilanz, unterschätztem Potenzial und begrenztem Abwärtsrisiko könnten 2026 zu den großen Gewinnern zählen. Die Gefahr einer schärferen Korrektur bleibt real, gerade für passiv aufgestellte Investoren.

In unserem neuen Spezialreport stellen wir fünf Aktien vor, die genau jetzt das Potenzial für überdurchschnittliche Renditen bieten. Stark, günstig und bislang kaum im Fokus.

Jetzt kostenlosen Report herunterladen – bevor es andere tun!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.